Application of neoadjuvant double-targeted therapy of pertuzumab and trastuzumab in the clinical treatment of HER2 positive breast cancer
Objective To investigate the effect of neoadjuvant double-targeted therapy of pertuzumab and trastuzumab in the clinical treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer.Methods 102 patients with HER2 positive breast cancer admitted to our hospital from Jan 2021 to Dec 2023 were divided into the control group and the study group according to random number table method.Both groups received neoadjuvant chemotherapy,and on this basis,the control group(n=51)received treatment with trastuzumab,the study group(n=51)received double-targeted therapy with pertuzumab and trastuzumab.The efficacy,TFF1,human ubiquitin conjugating enzyme E2C(UBE2C),immune indexes,quality of life and adverse reactions were compared between the two groups.Results The objective remission rate of the study group was higher than that of the control group(86.27%vs.66.67%,P<0.05).After treatment,TFF1 and UBE2C in the study group were lower than those before treatment and in the control group(P<0.05).After treatment,the levels of CD3+,CD4+T lymphocytes and CD4+/CD8+in the study group were lower than before treatment,but CD8+T limphocytes was higher than before treatment,and the levels of CD3+,CD4+T lymphocytes and CD4+/CD8+were higher than that of the control group,and the level CD8+T lymphocytes was lower than that of the control group(P<0.05).After treatment,the scores of quality of life in the study group were higher than those before treatment and in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The neoadjuvant double-targeted therapy of pertuzumab and trastuzumab is effective in the clinical treatment of HER2 positive breast cancer,With high safety,it can significantly reduce the expression of oncogenes in patients and reduce the influence on the immune function of the body.
Breast cancerHuman epidermal growth factor receptor-2PertuzumabTrastuzumab
万方数据
维普
